Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 4/20 | 0.33 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2994088 | 0.89 | GBA1 (0.34) | EGFRMCHR2MCHR1GBA1CISD1 | |
| SCHEMBL2989491 | 0.86 | EGFR (0.34) | EGFRMCHR1GBA1CISD1 | |
| Trifluoroacetic Acid SCHEMBL4586305 | 0.86 | SRC (0.35) | EGFR | |
| Trifluoroacetic Acid SCHEMBL2995873 | 0.86 | SRC (0.35) | EGFR | |
| Trifluoroacetic Acid SCHEMBL2988931 | 0.86 | GBA1 (0.39) | EGFRMCHR1GBA1 | |
| Trifluoroacetic Acid SCHEMBL2991042 | 0.85 | EGFR (0.33) | EGFRMCHR2MCHR1GBA1CISD1 | |
| Trifluoroacetic Acid SCHEMBL2991046 | 0.85 | EGFR (0.33) | EGFRMCHR2MCHR1GBA1CISD1 | |
| SCHEMBL2988362 | 0.85 | FABP3 (0.39) | FABP3FABP4FABP5CISD1 | |
| Trifluoroacetic Acid SCHEMBL2998142 | 0.84 | FABP3 (0.43) | FABP3FABP4FABP5CISD1 | |
| SCHEMBL4586161 | 0.81 | PTGDR2 (0.34) | EGFRMCHR1GBA1CISD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214455-A1 | Novel Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | claimed |
| EP-1879563-A4 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-07-16 | — | — | EP | claimed |
| EP-1879563-A2 | NOVEL CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-01-23 | — | — | EP | claimed |
| WO-2006132739-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-14 | — | — | WO | claimed |
| US-20100184774-A1 | METHODS OF TREATMENT | SMITHKLINE BEECHAM CORPORATION | 2010-07-22 | — | — | US | disclosed |
| EP-2164494-A1 | METHODS OF TREATMENT | GlaxoSmithKline LLC (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008150837-A1 | METHODS OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080214455-A1 | Novel Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| EP-1879563-A4 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1879563-A2 | NOVEL CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006132739-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214455-A1 | Novel Chemical Compounds | HIPK3, HIPK1, HIPK4 | FABP3 263/4885FABP4 2558/4885FABP5 1941/4885 |
| US-20100184774-A1 | METHODS OF TREATMENT | OPRL1, BRCA1, PKD1 | FABP3 3153/4885FABP4 393/4885FABP5 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.